RESUMEN
Chemotherapy-induced cognitive impairment such as memory impairment and concentration problems are now extensively recognized as side effects of chemotherapy. These problems reduce the quality of life in patients. Therefore, the present study aims to examine the effects of calcitriol supplementation (100 ng/kg /day for five weeks) on cognitive impairment, behavioral deficits, and hippocampal brain-derived neurotrophic factor (BDNF) changes following cisplatin treatment (5 mg/kg/ once a week for five weeks). We also determined the impact of cisplatin and calcitriol administration on reaction time against the thermal stimulus and muscle strength. Our findings showed that cisplatin administration resulted in a significant increase in anxiety-like behaviors. Treatment of rats with cisplatin also impaired performance in the passive avoidance and novel object recognition tasks which are indicating cognitive deficits. Co-administration of calcitriol prevented the cisplatin-induced behavioral and cognitive impairments. Cisplatin exposure also resulted in enhanced reaction time to the thermal stimulus and decreased muscle ability. Besides, hippocampal BDNF levels were reduced in cisplatin-treated rats; however, calcitriol alleviated these effects of cisplatin and up-regulated BDNF mRNA in the hippocampus. In addition, calcitriol alone indicated a significant change in BDNF level compared to the control group. We conclude that increased hippocampal BDNF mediates the beneficial effects of calcitriol against neurotoxicity in cisplatin-exposed rats. However, further studies are required to explore the other mechanisms that mediate the beneficial effect of calcitriol.
Asunto(s)
Antineoplásicos/efectos adversos , Síntomas Conductuales/tratamiento farmacológico , Factor Neurotrófico Derivado del Encéfalo/efectos de los fármacos , Calcitriol/farmacología , Cisplatino/efectos adversos , Disfunción Cognitiva/tratamiento farmacológico , Síndromes de Neurotoxicidad/tratamiento farmacológico , Animales , Conducta Animal/efectos de los fármacos , Síntomas Conductuales/inducido químicamente , Síntomas Conductuales/metabolismo , Calcitriol/administración & dosificación , Hormonas y Agentes Reguladores de Calcio , Disfunción Cognitiva/inducido químicamente , Disfunción Cognitiva/metabolismo , Suplementos Dietéticos , Modelos Animales de Enfermedad , Masculino , Síndromes de Neurotoxicidad/metabolismo , Ratas , Regulación hacia ArribaRESUMEN
Schizophrenia is a serious mental disorder requiring lifelong treatment. While medications are available that are effective in treating some patients, individual treatment responses can vary, with some patients exhibiting resistance to one or multiple drugs. Currently, little is known about the causes of the difference in treatment response observed among individuals with schizophrenia, and satisfactory markers of poor response are not available for clinical practice. Here, we studied the changes in the levels of 322 blood plasma lipids between two time points assessed in 92 individuals diagnosed with schizophrenia during their inpatient treatment and their association with the extent of symptom improvement. We found 20 triglyceride species increased in individuals with the least improvement in Positive and Negative Syndrome Scale (PANSS) scores, but not in those with the largest reduction in PANSS scores. These triglyceride species were distinct from the rest of the triglyceride species present in blood plasma. They contained a relatively low number of carbons in their fatty acid residues and were relatively low in abundance compared to the principal triglyceride species of blood plasma.
Asunto(s)
Antipsicóticos/efectos adversos , Síntomas Conductuales/epidemiología , Biomarcadores/sangre , Lipidómica/métodos , Esquizofrenia/tratamiento farmacológico , Triglicéridos/sangre , Adolescente , Adulto , Síntomas Conductuales/sangre , Síntomas Conductuales/inducido químicamente , Síntomas Conductuales/diagnóstico , Femenino , Humanos , Pacientes Internos/psicología , Pacientes Internos/estadística & datos numéricos , Masculino , Federación de Rusia/epidemiología , Esquizofrenia/patología , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Levetiracetam is a relatively new-generation antiseizure drug approved for the treatment of focal and generalized seizures. Despite its favorable side effect profile and minimal drug-drug interactions, neuropsychiatric side effects are reported in up to 13% of children. A few case series have suggested that supplementation of pyridoxine may mitigate these side effects, but controlled trials are lacking. To address this issue, a randomized interventional study was carried out in a pediatric tertiary hospital to qualify and quantify the potential beneficial effect of pyridoxine in attenuating the neuropsychiatric side effects of levetiracetam in children. METHODS: A total of 105 children with epilepsy who were taking levetiracetam (as a monotherapy or an adjunct) who showed behavioral symptoms coinciding with the start of levetiracetam, were included. Patients randomly and blindly received either a therapeutic (pyridoxine group, 46 of 105, 44%) or a homeopathic dose of pyridoxine (placebo, 59 of 105, 56%). A 30-item behavioral checklist was used to qualify and quantify the behavioral side effects at baseline and at different time points following initiation of treatment. RESULTS: Both placebo and pyridoxine groups experienced a statistical reduction in behavioral scores when compared with baseline. Our study indicated that although there was a placebo effect, the improvement in neuropsychiatric symptoms was more prominent in children who received therapeutic doses of pyridoxine. CONCLUSIONS: These data provide clinicians with pertinent evidence-based information that suggests that a trial of pyridoxine in patients who experience behavioral side effects due to the use of levetiracetam may avoid unnecessary change of antiseizure medications.
Asunto(s)
Anticonvulsivantes/efectos adversos , Síntomas Conductuales/inducido químicamente , Síntomas Conductuales/tratamiento farmacológico , Levetiracetam/efectos adversos , Piridoxina/farmacología , Complejo Vitamínico B/farmacología , Niño , Preescolar , Método Doble Ciego , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/tratamiento farmacológico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/etiología , Femenino , Humanos , Masculino , Evaluación de Resultado en la Atención de Salud , Piridoxina/administración & dosificación , Complejo Vitamínico B/administración & dosificaciónRESUMEN
AIM: To identify and evaluate the evidence documenting the association between neonatal morphine and later childhood neuropsychological development. METHOD: We conducted a systematic literature search of eight electronic databases from inception until June 2019. We included all randomized controlled trials (RCTs) and cohort studies recruiting neonates who received morphine treatment, and measuring neuropsychological development outcomes with a minimum follow-up of 6 months. RESULTS: Twelve separate reports from three RCTs and five cohort studies met our inclusion criteria. Owing to the small number of the included trials and the variable study designs, a meta-analysis was not performed. The findings from this review indicated that neonatal morphine use had no adverse effects on behaviour, cognition, motor, and executive function development at 8 to 9 years and earlier; except for the inconsistent conclusions on internalizing behavioural problems at 5 to 7 years and cognitive and motor developments at 18 months. INTERPRETATION: Why a child needs morphine may have a more profound impact on later neuropsychological development than morphine itself. The small number, high heterogeneity, and limitations of the included studies limit confidence in the result of this systematic review.
Asunto(s)
Síntomas Conductuales/inducido químicamente , Conducta Infantil/efectos de los fármacos , Desarrollo Infantil/efectos de los fármacos , Cognición/efectos de los fármacos , Función Ejecutiva/efectos de los fármacos , Morfina/efectos adversos , Narcóticos/efectos adversos , Desempeño Psicomotor/efectos de los fármacos , Niño , Preescolar , Humanos , Lactante , Recién NacidoRESUMEN
Importance: In light of increasing cannabis use among pregnant women, the US Surgeon General recently issued an advisory against the use of marijuana during pregnancy. Objective: To evaluate whether cannabis use during pregnancy is associated with adverse outcomes among offspring. Design, Setting, and Participants: In this cross-sectional study, data were obtained from the baseline session of the ongoing longitudinal Adolescent Brain and Cognitive Development Study, which recruited 11â¯875 children aged 9 to 11 years, as well as a parent or caregiver, from 22 sites across the United States between June 1, 2016, and October 15, 2018. Exposure: Prenatal cannabis exposure prior to and after maternal knowledge of pregnancy. Main Outcomes and Measures: Symptoms of psychopathology in children (ie, psychotic-like experiences [PLEs] and internalizing, externalizing, attention, thought, and social problems), cognition, sleep, birth weight, gestational age at birth, body mass index, and brain structure (ie, total intracranial volume, white matter volume, and gray matter volume). Covariates included familial (eg, income and familial psychopathology), pregnancy (eg, prenatal exposure to alcohol and tobacco), and child (eg, substance use) variables. Results: Among 11â¯489 children (5997 boys [52.2%]; mean [SD] age, 9.9 [0.6] years) with nonmissing prenatal cannabis exposure data, 655 (5.7%) were exposed to cannabis prenatally. Relative to no exposure, cannabis exposure only before (413 [3.6%]) and after (242 [2.1%]) maternal knowledge of pregnancy were associated with greater offspring psychopathology characteristics (ie, PLEs and internalizing, externalizing, attention, thought and, social problems), sleep problems, and body mass index, as well as lower cognition and gray matter volume (all |ß| > 0.02; all false discovery rate [FDR]-corrected P < .03). Only exposure after knowledge of pregnancy was associated with lower birth weight as well as total intracranial volume and white matter volumes relative to no exposure and exposure only before knowledge (all |ß| > 0.02; all FDR-corrected P < .04). When including potentially confounding covariates, exposure after maternal knowledge of pregnancy remained associated with greater PLEs and externalizing, attention, thought, and social problems (all ß > 0.02; FDR-corrected P < .02). Exposure only prior to maternal knowledge of pregnancy did not differ from no exposure on any outcomes when considering potentially confounding variables (all |ß| < 0.02; FDR-corrected P > .70). Conclusions and Relevance: This study suggests that prenatal cannabis exposure and its correlated factors are associated with greater risk for psychopathology during middle childhood. Cannabis use during pregnancy should be discouraged.
Asunto(s)
Síntomas Conductuales/inducido químicamente , Uso de la Marihuana/efectos adversos , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Síntomas Conductuales/epidemiología , Niño , Estudios Transversales , Femenino , Humanos , Masculino , Uso de la Marihuana/epidemiología , Embarazo , Efectos Tardíos de la Exposición Prenatal/epidemiología , Estados Unidos/epidemiologíaAsunto(s)
Corticoesteroides/efectos adversos , Antirretrovirales/efectos adversos , Azitromicina/efectos adversos , Síntomas Conductuales/inducido químicamente , Tratamiento Farmacológico de COVID-19 , Disfunción Cognitiva/inducido químicamente , Delirio/inducido químicamente , Factores Inmunológicos/efectos adversos , Síndromes de Neurotoxicidad/etiología , Antirretrovirales/toxicidad , COVID-19/complicaciones , HumanosRESUMEN
Glufosinate ammonium (GLA) is a widely used organophosphate herbicide, which could be commonly detected in body fluids of both pregnant women and newborns. Existing evidences indicate that GLA has reproductive toxicity, while data concerning the effects of prenatal GLA exposure on neurodevelopment is rather limited. Here we employed a mouse model exposed to GLA prenatally. Reduced locomotor activity, impaired memory formation and autism-like behaviors were observed in the treatment group. Marked alteration in gut microbiome of the treatment offspring mice could be found at 4th week, and seemed to recover over time. Fecal metabolomics analysis indicated remarkable changes in microbiome-related metabolism in the treatment group, which could be the cause of behavioral abnormality in mice. Present study suggested that prenatal exposure to GLA disturbed gut microbiome and metabolism, and thereby induced behavioral abnormalities in mice.
Asunto(s)
Aminobutiratos/toxicidad , Síntomas Conductuales/inducido químicamente , Microbioma Gastrointestinal/efectos de los fármacos , Herbicidas/toxicidad , Trastornos Psicomotores/inducido químicamente , Contaminantes Químicos del Agua/toxicidad , Animales , Conducta Animal/efectos de los fármacos , Síntomas Conductuales/prevención & control , Trasplante de Microbiota Fecal , Femenino , Locomoción/efectos de los fármacos , Masculino , Exposición Materna , Ratones Endogámicos ICR , Embarazo , Efectos Tardíos de la Exposición Prenatal , Trastornos Psicomotores/prevención & control , Interacción Social/efectos de los fármacosRESUMEN
Glutamate is an amino acid that functions as an excitatory neurotransmitter. It has also been associated with somatic and psychiatric distress and is implicated in the pathophysiology of psychiatric disorders such as schizophrenia. Ingestion of dietary glutamate, such as monosodium glutamate (MSG), has been mechanistically linked with greater distress among patients with chronic pain conditions, though findings have been equivocal. Preliminary research suggests that an MSG-restricted diet confers beneficial effects on somatic symptoms and well-being for some individuals with chronic pain conditions. In addition to associations with somatic distress, glutamate has been associated with the onset and progression of psychiatric symptoms. Thus, the role of dietary glutamate in psychiatric distress represents an underdeveloped and potentially important area for future research aimed at clarifying pathophysiological mechanisms and identifying targets for dietary intervention in psychiatric illnesses.
Asunto(s)
Síntomas Conductuales/inducido químicamente , Fármacos actuantes sobre Aminoácidos Excitadores/efectos adversos , Alimentos/efectos adversos , Glutamatos/efectos adversos , Animales , Aromatizantes/efectos adversos , Humanos , Glutamato de Sodio/efectos adversosRESUMEN
Clinical studies suggest that the antiepileptic drug (AED) brivaracetam (BRV) is associated with fewer behavioral and psychiatric adverse events (AEs) compared with levetiracetam (LEV) in treating epilepsy. There are, however, few comparative studies of treatment-emergent AEs between patients on BRV with preexisting psychiatric or behavioral comorbidities to those without. Our study compared longer-term tolerability over a 26-month period between these patient groups and assessed the overall efficacy of BRV as add-on therapy. Patients with intellectual disabilities in whom the prevalence of epilepsy is higher, are often excluded from randomized controlled trials, and our study further assessed comparative effectiveness between this patient group and those with normal range intellect. We collected prospective data on 134 patients prescribed add-on BRV for epilepsy at a tertiary UK center over a 26-month period. All patients had previously received LEV. Sixty-three patients were on LEV at the start of the data collection period. Levetiracetam was withdrawn and switched to BRV in 39 patients because of inefficacy and 24 patients because of behavioral or psychiatric side effects. Seventy-three patients (54%) had a preexisting psychiatric or behavioral disorder compared with 64 patients (46%) without. The retention rate at last follow-up [mean: 11â¯months (0.5-26â¯months)] was 60% in the psychiatric/behavioral disorders group versus 67% in those without (pâ¯=â¯0.68). Forty-one patients had diagnosed intellectual disabilities. The retention rate was 66% in this group versus 62% in patients without intellectual disabilities (pâ¯=â¯0.36). The commonest treatment-emergent AEs were somnolence (26%), aggression (23%), and depression (9%). There were similar frequencies reported for these specific events across the groups. The proportion with a 50% responder rate was 29% in patients with focal epilepsy and 47% in patients with generalized and combined focal and generalized epilepsies. However, fifteen patients (11%) reported increased seizure activity leading to withdrawal of treatment. This study showed evidence that BRV may be an effective adjunctive therapy in patients with drug-resistant focal or generalized epilepsies whose seizures have previously not responded or tolerated LEV therapy. We demonstrated a higher incidence of treatment-emergent AEs leading to lower retention rates compared with previous studies across all patient groups. There were, however, no significant differences in tolerability between patients with preexisting psychiatric or behavioral comorbidities, or intellectual disability to those without.
Asunto(s)
Anticonvulsivantes/farmacología , Síntomas Conductuales , Epilepsias Parciales/tratamiento farmacológico , Epilepsia Generalizada/tratamiento farmacológico , Discapacidad Intelectual , Levetiracetam/farmacología , Trastornos Mentales , Pirrolidinonas/farmacología , Adolescente , Adulto , Anciano , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/efectos adversos , Síntomas Conductuales/inducido químicamente , Síntomas Conductuales/epidemiología , Comorbilidad , Quimioterapia Combinada , Epilepsias Parciales/epidemiología , Epilepsia Generalizada/epidemiología , Femenino , Humanos , Discapacidad Intelectual/epidemiología , Levetiracetam/administración & dosificación , Levetiracetam/efectos adversos , Masculino , Trastornos Mentales/inducido químicamente , Trastornos Mentales/epidemiología , Persona de Mediana Edad , Estudios Prospectivos , Pirrolidinonas/administración & dosificación , Pirrolidinonas/efectos adversos , Resultado del Tratamiento , Adulto JovenRESUMEN
Cannabis legalization has led to significant health consequences, particularly to patients in emergency departments and hospitals in Colorado. The most concerning include psychosis, suicide, and other substance abuse. Deleterious effects on the brain include decrements in complex decision-making, which may not be reversible with abstinence. Increases in fatal motor vehicle collisions, adverse effects on cardiovascular and pulmonary systems, inadvertent pediatric exposures, cannabis contaminants exposing users to infectious agents, heavy metals, and pesticides, and hash-oil burn injuries in preparation of drug concentrates have been documented. Cannabis dispensary workers ("budtenders") without medical training are giving medical advice that may be harmful to patients. Cannabis research may offer novel treatment of seizures, spasticity from multiple sclerosis, nausea and vomiting from chemotherapy, chronic pain, improvements in cardiovascular outcomes, and sleep disorders. Progress has been slow due to absent standards for chemical composition of cannabis products and limitations on research imposed by federal classification of cannabis as illegal. Given these factors and the Colorado experience, other states should carefully evaluate whether and how to decriminalize or legalize non-medical cannabis use.
Asunto(s)
Servicio de Urgencia en Hospital/estadística & datos numéricos , Uso de la Marihuana/efectos adversos , Uso de la Marihuana/tendencias , Accidentes de Tránsito/tendencias , Síntomas Conductuales/inducido químicamente , Cannabis/química , Colorado/epidemiología , Conducir bajo la Influencia/tendencias , Contaminación de Medicamentos , Sobredosis de Droga/epidemiología , Hospitalización/tendencias , Humanos , Legislación de Medicamentos , Trastornos Mentales/inducido químicamente , Servicios de Salud Mental/tendencias , Intoxicación/epidemiología , Vómitos/epidemiologíaRESUMEN
BACKGROUND: Compelling animal and clinical studies support the N-methyl-D-aspartate receptor (NMDAR) hypofunction hypothesis of schizophrenia and suggest promising pharmacological agents to ameliorate negative and cognitive symptoms of schizophrenia, including sarcosine, a glycine transporter-1 inhibitor. AIMS AND METHODS: It is imperative to evaluate the therapeutic potential of sarcosine in animal models, which provide indispensable tools for testing drug effects in detail and elucidating the underlying mechanisms. In this study, a series of seven experiments was conducted to investigate the effect of sarcosine in ameliorating behavioral deficits and the underlying mechanism in pharmacological (i.e., MK-801-induced) and genetic (i.e., serine racemase-null mutant (SR-/-) mice) NMDAR hypofunction models. RESULTS: In Experiment 1, the acute administration of 500/1000 mg/kg sarcosine (i.p.) had no adverse effects on motor function and serum biochemical responses. In Experiments 2-4, sarcosine significantly alleviated MK-801-induced (0.2 mg/kg) brain abnormalities and behavioral deficits in MK-801-induced and SR-/- mouse models. In Experiment 5, the injection of sarcosine enhanced CSF levels of glycine and serine in rat brain. In Experiments 6-7, we show for the first time that sarcosine facilitated NMDAR-mediated hippocampal field excitatory postsynaptic potentials and influenced the movement of surface NMDARs at extrasynaptic sites. CONCLUSIONS: Sarcosine effectively regulated the surface trafficking of NMDARs, NMDAR-evoked electrophysiological activity, brain glycine levels and MK-801-induced abnormalities in the brain, which contributed to the amelioration of behavioral deficits in mouse models of NMDAR hypofunction.
Asunto(s)
Síntomas Conductuales/tratamiento farmacológico , Encefalopatías/tratamiento farmacológico , Proteínas de Transporte de Glicina en la Membrana Plasmática/agonistas , Receptores de N-Metil-D-Aspartato/efectos de los fármacos , Sarcosina/farmacología , Esquizofrenia/tratamiento farmacológico , Animales , Síntomas Conductuales/inducido químicamente , Encefalopatías/inducido químicamente , Modelos Animales de Enfermedad , Maleato de Dizocilpina/farmacología , Antagonistas de Aminoácidos Excitadores/farmacología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Racemasas y Epimerasas/genética , Sarcosina/administración & dosificación , Esquizofrenia/metabolismo , Esquizofrenia/patología , Esquizofrenia/fisiopatologíaAsunto(s)
Síntomas Conductuales/tratamiento farmacológico , Encefalopatías/tratamiento farmacológico , Intoxicación por Monóxido de Carbono/complicaciones , Disfunción Cognitiva/tratamiento farmacológico , Donepezilo/farmacología , Intento de Suicidio , Adulto , Síntomas Conductuales/inducido químicamente , Encefalopatías/inducido químicamente , Inhibidores de la Colinesterasa/farmacología , Disfunción Cognitiva/inducido químicamente , Humanos , Persona de Mediana Edad , TaiwánRESUMEN
PURPOSE: In 2007, Ministry of Health, Labour and Welfare (MHLW) warned to refrain from prescribing oseltamivir for teenagers when two Japanese teenagers with influenza fell from a high-rise building after taking oseltamivir. Revisions of the warning texts of anti-influenza drugs were discussed by the Subcommittee of Pharmaceutical Affairs and Food Sanitation Council, MHLW, based on the studies and trends of anti-influenza medication over the last 10 years. METHOD: The research group led by Dr Nobuhiko Okabe conducted nationwide survey since the 2007/2008 influenza season. The results of Japanese and foreign epidemiological and non-clinical studies of abnormal behaviors in influenza patients since 2009 were reviewed. RESULT: Severe abnormal behaviors have been reported in influenza patients taking all types of anti-influenza drugs, as well as in untreated patients. There are some risks to patients whether treated with any anti-influenza drug, or non-treated though it is still not possible to rule out a potential causal relationship between abnormal behaviors and anti-influenza drugs. 70% of abnormal behaviors occurred within two days after the onset of fever. No difference was found between anti-influenza drugs treated and non-treated patients. In patients receiving oseltamivir and other anti-influenza drugs, the frequency of abnormal behaviors is not clearly different between teenagers and patients under 10 years old. CONCLUSION: The specific "boxed warning" and the restriction only for oseltamivir that should not be used for teenagers was lifted. Therefore, the labeling of all anti-influenza drugs carry a consistent warning about the potential for abnormal behaviors in Japan.
Asunto(s)
Antivirales/efectos adversos , Síntomas Conductuales/epidemiología , Etiquetado de Medicamentos , Gripe Humana/tratamiento farmacológico , Oseltamivir/efectos adversos , Accidentes por Caídas , Adolescente , Factores de Edad , Antivirales/administración & dosificación , Síntomas Conductuales/inducido químicamente , Síntomas Conductuales/diagnóstico , Niño , Preescolar , Femenino , Humanos , Japón/epidemiología , Masculino , Oseltamivir/administración & dosificación , Índice de Severidad de la Enfermedad , Adulto JovenRESUMEN
BACKGROUND: Even though abnormal behavior related with influenza and neuraminidase inhibitors (NI) has been discussed, the risks of acetaminophen and co-administration of NI and acetaminophen have not been examined. This study assesses those risks. MATERIALS AND METHODS: All cases of patients with influenza who present with severe abnormal behavior are reported by physicians of all clinics and hospitals throughout Japan. The numbers of people diagnosed as having influenza, whether prescribed NI and acetaminophen or not, were extracted from the National Database of Electronic Medical Claims (NDBEMC). The study period was from September 2009 to March 2016. RESULTS: We found two consistent results among four combinations of age class and severity. The one was that patients who did not use NI or acetaminophen showed significantly higher incidence of abnormal behavior than zanamivir with acetaminophen, another one was that patients with oseltamivir only has higher incidence than zanamivir with acetaminophen. Concerning about acetaminophen, the use of it significantly decrease risk for severe and the most severe instances in 5-9-year-old patients with laninamivir and the severe instances in 10-19-year-old patients with zanamivir. DISCUSSION: We also demonstrated that acetaminophen alone or co-administered with NI does not seem to raise the risk of abnormal behavior in influenza patients.
Asunto(s)
Acetaminofén/efectos adversos , Antivirales/efectos adversos , Síntomas Conductuales/epidemiología , Inhibidores Enzimáticos/efectos adversos , Gripe Humana/tratamiento farmacológico , Adolescente , Factores de Edad , Síntomas Conductuales/inducido químicamente , Niño , Quimioterapia Combinada/efectos adversos , Quimioterapia Combinada/métodos , Femenino , Guanidinas , Humanos , Incidencia , Gripe Humana/psicología , Japón/epidemiología , Masculino , Neuraminidasa/antagonistas & inhibidores , Oseltamivir/efectos adversos , Piranos , Factores de Riesgo , Ácidos Siálicos , Zanamivir/efectos adversos , Zanamivir/análogos & derivadosRESUMEN
Repeated administration of morphine profoundly influences the dopaminergic and cholinergic systems in the nucleus accumbens [including the shell of the nucleus accumbens (NAcS)]. Further, dopamine release is regulated by the cholinergic system, especially the M4 receptor. Drug priming is one of the main factors that induces relapse in drug addiction. The present study first investigated how activation of the M4 receptor in the NAcS affects the expression of morphine-induced behavioral sensitization, through the administration of an M4 agonist (LY2033298) and antagonist (tropicamide), as well as a combination of an acetylcholinesterase inhibitor and M4 antagonist (huperzine-A + tropicamide). Additionally, the influence of a dopamine receptor agonist, in conjunction with an M4 agonist (i.e., SKF38393 + LY2033298), was also examined. Behavioral sensitization was established by exposure to 5 mg/kg morphine once every three days for a total of three exposures. The expression of behavioral sensitization was challenged by 5 mg/kg morphine. Results showed that (1) microinjection of the M4 receptor agonist LY2033298 (0.2 µg/side), but not the antagonist tropicamide (5, 10, or 20 µM/side) into the NAcS blocked the expression of behavioral sensitization; (2) tropicamide (20 µM/side) reversed the inhibition effect of huperzine-A on this behavior; and (3) SKF38393 (1 µg/side) reversed the inhibitory effect of LY2033298 on the expression of morphine-induced behavioral sensitization. These results suggest that the cholinergic M4 receptor in the NAcS plays an important role in the morphine-induced expression of behavioral sensitization through the regulation of dopamine function in rats.
Asunto(s)
Síntomas Conductuales/inducido químicamente , Dopamina/metabolismo , Morfina/efectos adversos , Narcóticos/efectos adversos , Núcleo Accumbens/efectos de los fármacos , Receptor Muscarínico M4/metabolismo , 2,3,4,5-Tetrahidro-7,8-dihidroxi-1-fenil-1H-3-benzazepina/farmacología , Animales , Antipsicóticos/farmacología , Agonistas de Dopamina/farmacología , Relación Dosis-Respuesta a Droga , Locomoción/efectos de los fármacos , Masculino , Microinyecciones , Antagonistas Muscarínicos/farmacología , Ácidos Nicotínicos/farmacología , Ratas , Ratas Wistar , Tiofenos/farmacología , Tropicamida/farmacologíaRESUMEN
Synthetic opioids (SO) are a major risk for public health across the world. These drugs can be divided into 2 categories, pharmaceutical and non-pharmaceutical fentanyls. A new generation of SO has emerged on the drug market since 2010. North America is currently facing an opioid epidemic of morbi-mortality, caused by over-prescription of opioids, illegally diverted prescribed medicines, the increasing use of heroin and the emergence of SO. Furthermore, this opioid crisis is also seen in Europe. SO are new psychoactive substances characterized by different feature such as easy availability on the Internet, low price, purity, legality, and lack of detection in laboratory tests. They have not been approved or are not recommended for human use. Opioid misuse is associated with somatic and psychiatric complications. For many substances, limited pharmacological information is available, increasing the risk of harmful adverse events. Health actors and the general population need to be clearly informed of the potential risks and consequences of the diffusion and use of SO.
Asunto(s)
Analgésicos Opioides/efectos adversos , Síntomas Conductuales/inducido químicamente , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Fentanilo/efectos adversos , Trastornos Relacionados con Sustancias , Drogas Sintéticas/efectos adversos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Fentanilo/análisis , Humanos , Trastornos Relacionados con Sustancias/epidemiologíaRESUMEN
Doxorubicin (DOX) is a broad-spectrum antitumor drug while its use is limited due to its neurobiological side effects associated with depression. We investigated the neuroprotective efficacy of dl-3-n-butylphthalide (dl-NBP) against DOX-induced anxiety- and depression-like behaviors in rats. dl-NBP was given (30 mg/kg) daily by gavage over three weeks starting seven days before DOX administration. Elevated plus maze (EPM) test, forced swimming test (FST), and sucrose preference test (SPT) were performed to assess anxiety- and depression-like behaviors. Our study showed that the supplementation of dl-NBP significantly mitigated the behavioral changes induced by DOX. To further explore the mechanism of neuroprotection induced by dl-NBP, several biomarkers including oxidative stress markers, endoplasmic reticulum (ER) stress markers, and neuroinflammatory cytokines in the hippocampus were quantified. The results showed that dl-NBP treatment alleviated DOX-induced neural apoptosis. Meanwhile, DOX-induced oxidative stress and ER stress in the hippocampus were significantly ameliorated in dl-NBP pretreatment group. Our study found that dl-NBP alleviated the upregulation of malondialdehyde (MDA), nitric oxide (NO), CHOP, glucose-regulated protein 78 kD (GRP-78), and caspase-12 and increased the levels of reduced glutathione (GSH) and activities of catalase (CAT), glutathione reductase (GR), and glutathione peroxidase (GPx) in the hippocampus of rats exposed to DOX. Additionally, the gene expression of interleukin-6 (IL-6), interleukin-1ß (IL-1ß), and tumor necrosis factor-alpha (TNF-α) and protein levels of inducible nitric oxide synthase (iNOS) were significantly increased in DOX-treated group, whereas DOX-induced neuroinflammation was significantly attenuated in dl-NBP supplementation group. In conclusion, dl-NBP could alleviate DOX-induced anxiety- and depression-like behaviors via attenuating oxidative stress, ER stress, inflammatory reaction, and neural apoptosis, providing a basis as a therapeutic potential against DOX-induced neurotoxicity.